The role of indoleamine 2,3 dioxygenase in the induction of immune tolerance in organ transplantation

Transplantation Reviews

Volumn 24, Issue 3, 2010, Pages 160-165

  Palafox, Damian ^a   Llorente, Luis ^a   Alberú, Josefina ^a   Torres Machorro, Adriana ^a   Camorlinga, Nancy ^a   Rodríguez, Cinthya ^a   Granados, Julio ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; TRYPTOPHAN;

ALLOTRANSPLANTATION; APOPTOSIS; COMPOSITE GRAFT; CYTOKINE RELEASE; ENZYME INDUCTION; ENZYME MECHANISM; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HEALTH CARE PERSONNEL; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; IMMUNOLOGY; PHYSIOLOGY; TRANSPLANTATION TOLERANCE;

ANIMALS; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 77954386836     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.04.003     Document Type: Review

References (51)

1. Hayaishi O. Indoleamine 2,3-dioxygenase-with special reference to the mechanism of interferon action. Biken J 1985, 28:39-49.
2. Yoshida R., Hayaishi O. Indoleamine 2,3-dioxygenase. Methods Enzymol 1987, 142:188-195.
3. Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol Cell Biol 2003, 81:247-265.
4. Thomas S.R., Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999, 4:199-220.
5. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
6. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions?. Immunity 2003, 19:5-8.
7. Hackstein H., Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004, 4:24-34.
8. von Bernstorff W., Voss M., Freichel S., et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001, 7(3 Suppl):925s-932s.
9. Koneru M., Schaer D., Monu N., et al. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 2005, 174:1830-1840.
10. Becker J.C., Brabletz T., Kirchner T., et al. Negative transcriptional regulation in anergic T cells. Proc Natl Acad Sci U S A 1995, 92:2375-2378.
11. Munn D.H., Sharma M.D., Mellor A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004, 172:4100-4110.
12. Yoshida R., Urade Y., Nakata K., et al. Specific induction of indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide in the mouse lung. Arch Biochem Biophys 1981, 212:629-637.
13. Hucke C., MacKenzie C.R., Adjogble K.D., et al. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun 2004, 72:2723-2730.
14. Mellor A.L., Keskin D.B., Johnson T., et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002, 168:3771-3776.
15. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 1999, 20:469-473.
16. Mellor A.L., Munn D.H. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003, 170:5809-5813.
17. Munn D.H., Zhou M., Attwood J.T., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
18. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
19. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
20. Fontenot J.D., Rasmussen J.P., Gavin M.A., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
21. Fallarino F., Gizzi S., Mosci P., et al. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr Drug Metab 2007, 8:209-216.
22. Meloni F., Giuliano S., Solari N., et al. Indoleamine 2,3-dioxygenase in lung allograft tolerance. J Heart Lung Transplant 2009, 28:1185-1192.
23. Dai X., Zhu B.T. Suppression of T-cell response and prolongation of allograft survival in a rat model by tryptophan catabolites. Eur J Pharmacol 2009, 606:225-232.
24. Yu G., Dai H., Chen J., et al. Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J Gene Med 2008, 10:754-761.
25. Li J., Meinhardt A., Roehrich M.E., et al. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007, 293:H3415-H3423.
26. Hill M., Zagani R., Voisine C., et al. Nitric oxide and indoleamine 2,3-dioxygenase mediate CTLA4Ig-induced survival in heart allografts in rats. Transplantation 2007, 84:1060-1063.
27. Pillarisetty V.G., Shah A.B., Miller G., et al. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 2004, 172:1009-1017.
28. Laurence J.M., Wang C., Zheng M., et al. Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. Liver Transpl 2009, 15:233-241.
29. Lin Y.C., Chen C.L., Nakano T., et al. Immunological role of indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance. J Gastroenterol Hepatol 2008, 23(7 Pt 2):e243-e250.
30. Brandacher G., Cakar F., Winkler C., et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007, 71:60-70.
31. Cook C.H., Bickerstaff A.A., Wang J.J., et al. Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO. J Immunol 2008, 180:3103-3112.
32. Bickerstaff A.A., Wang J.J., Pelletier R.P., et al. Murine renal allografts: spontaneous acceptance is associated with regulated T cell-mediated immunity. J Immunol 2001, 167:4821-4827.
33. Degauque N., Lair D., Dupont A., et al. Dominant tolerance to kidney allografts induced by anti-donor MHC class II antibodies: cooperation between T and non-T CD103+ cells. J Immunol 2006, 176:3915-3922.
34. Blazar B.R., Taylor P.A., Linsley P.S., et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994, 83:3815-3825.
35. Yu X.Z., Bidwell S.J., Martin P.J., et al. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000, 164:4564-4568.
36. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
37. Chakraverty R., Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 2007, 110:9-17.
38. Jasperson L.K., Bucher C., Panoskaltsis-Mortari A., et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008, 111:3257-3265.
39. Jasperson L.K., Bucher C., Panoskaltsis-Mortari A., et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009, 114:5062-5070.
40. Ravindra K.V., Wu S., Bozulic L., et al. Composite tissue transplantation: a rapidly advancing field. Transplant Proc 2008, 40:1237-1248.
41. Dubernard J.M., Owen E., Herzberg G., et al. Human hand allograft: report on first 6 months. Lancet 1999, 353:1315-1320.
42. Gazarian A., Abrahamyan D.O., Petruzzo P., et al. [Hand allografts: experience from Lyon team]. Ann Chir Plast Esthet 2007, 52:424-435.
43. Lengele B.G., Testelin S., Dakpe S., et al. "Facial graft": about the first facial allotransplantation of composite tissues. Ann Chir Plast Esthet 2007, 52:457-484.
44. Devauchelle B., Badet L., Lengele B., et al. First human face allograft: early report. Lancet 2006, 368:203-209.
45. Devauchelle B., Lengele B.G., Moure C., et al. Mediatisation and "facial graft" or "to whom belongs the facial graft"?. Ann Chir Plast Esthet 2007, 52:528-530.
46. Eljaafari A., Badet L., Kanitakis J., et al. Isolation of regulatory T cells in the skin of a human hand-allograft, up to six years posttransplantation. Transplantation 2006, 82:1746-1748.
47. Hautz T., Brandacher G., Zelger B., et al. Indoleamine 2,3-dioxygenase and foxp3 expression in skin rejection of human hand allografts. Transplant Proc 2009, 41:509-512.
48. Yu G., Fang M., Gong M., et al. Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells. Transpl Immunol 2008, 18:208-219.
49. Chen W., Liang X., Peterson A.J., et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-5404.
50. Grohmann U., Orabona C., Fallarino F., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3:1097-1101.
51. Louis S., Braudeau C., Giral M., et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.